Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander DrilonTheodore W LaetschShivaani KummarSteven G DuBoisUlrik N LassenGeorge D DemetriMichael NathensonRobert C DoebeleAnna F FaragoAlberto S PappoBrian TurpinAfshin DowlatiMarcia S BroseLeo MascarenhasNoah FedermanJordan BerlinWafik S El-DeiryChristina BaikJohn DeekenValentina BoniRamamoorthy NagasubramanianMatthew TaylorErin R RudzinskiFunda Meric-BernstamDavendra P S SohalPatrick C MaLuis E RaezJaclyn F HechtmanRyma BenayedMarc LadanyiBrian B TuchKevin EbataScott CruickshankNora C KuMichael C CoxDouglas S HawkinsDavid S HongDavid M HymanPublished in: The New England journal of medicine (2018)
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).